Authors: Dr. Amita Joshi, Dr. Manish Nivsarkar
The lymphatics are the inaccessible reservoirs of HIV in human body. Efavirenz (EFV) is a BCS class II, ARV drug that undergoes extensive first pass metabolism. Two lipid based drug system were developed and evaluated for their lymphotropic ability. EFV SLN and EFV SMEDDS were formulated, developed and optimized as per their particle size, zeta potential, drug content, cloud point etc. The developed EFV SLNS and EFV SMEDDS were evaluated for lymphotropic potential in-vivo in rats using chylomicron flow blockers. Comparative pharmacokinetic profile reveals that oral administration of EFV SMEDDS results in higher rate and extent of drug absorption. Presence of significant amount of EFV in spleen from EFV SLN as well as EFV SMEDDS validates the lymphotropic potential of these two lipid based delivery system.
Keywords: Lymphotropic, chylomicron flow blockers, SLN, SMEDDS, Lymphatic targeting